Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows

Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
McKenzie Prillaman
McKenzie Prillaman
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.
McKenzie Prillaman
McKenzie Prillaman
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login